AR111491A1 - Métodos para tratar enfermedades pediátricas - Google Patents
Métodos para tratar enfermedades pediátricasInfo
- Publication number
- AR111491A1 AR111491A1 ARP180101099A ARP180101099A AR111491A1 AR 111491 A1 AR111491 A1 AR 111491A1 AR P180101099 A ARP180101099 A AR P180101099A AR P180101099 A ARP180101099 A AR P180101099A AR 111491 A1 AR111491 A1 AR 111491A1
- Authority
- AR
- Argentina
- Prior art keywords
- dose
- seq
- weeks
- antibody
- amino acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492031P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111491A1 true AR111491A1 (es) | 2019-07-17 |
Family
ID=62455814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101099A AR111491A1 (es) | 2017-04-28 | 2018-04-27 | Métodos para tratar enfermedades pediátricas |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3224280A1 (en) | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20230096620A1 (en) * | 2019-04-17 | 2023-03-30 | Millennium Pharmaceuticals, Inc. | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| WO2025177055A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Combination therapy for treating inflammatory bowel disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| ATE366809T1 (de) | 1995-02-10 | 2007-08-15 | Millennium Pharm Inc | Addressine der schleimhaut und der blutgefässe und ihre verwendung |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| AU2003248549B2 (en) | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| AU2003298661B2 (en) | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| ES2377979T3 (es) | 2004-09-03 | 2012-04-03 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
| EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| PE20120497A1 (es) | 2009-03-20 | 2012-05-14 | Amgen Inc | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| EP3978530A1 (en) * | 2015-02-26 | 2022-04-06 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| MA43755A (fr) * | 2016-03-14 | 2018-11-28 | Millennium Pharm Inc | Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte |
-
2018
- 2018-04-26 IL IL270201A patent/IL270201B2/en unknown
- 2018-04-26 KR KR1020197030615A patent/KR20190141148A/ko not_active Ceased
- 2018-04-26 AU AU2018256840A patent/AU2018256840A1/en not_active Abandoned
- 2018-04-26 BR BR112019022268-5A patent/BR112019022268A2/pt unknown
- 2018-04-26 EP EP18728257.9A patent/EP3615071A2/en active Pending
- 2018-04-26 JP JP2019557637A patent/JP2020517671A/ja not_active Withdrawn
- 2018-04-26 WO PCT/US2018/029579 patent/WO2018200818A2/en not_active Ceased
- 2018-04-26 CA CA3061320A patent/CA3061320A1/en active Pending
- 2018-04-26 KR KR1020257028168A patent/KR20250134146A/ko active Pending
- 2018-04-26 CN CN201880027856.4A patent/CN110612120A/zh active Pending
- 2018-04-26 MX MX2019012749A patent/MX2019012749A/es unknown
- 2018-04-26 US US16/608,895 patent/US20200179486A1/en active Pending
- 2018-04-27 TW TW112126603A patent/TW202342102A/zh unknown
- 2018-04-27 TW TW107114371A patent/TWI811216B/zh active
- 2018-04-27 AR ARP180101099A patent/AR111491A1/es not_active Application Discontinuation
-
2019
- 2019-10-24 MX MX2024012972A patent/MX2024012972A/es unknown
- 2019-10-24 MX MX2024003905A patent/MX2024003905A/es unknown
- 2019-10-24 MX MX2024003906A patent/MX2024003906A/es unknown
-
2023
- 2023-05-10 JP JP2023077997A patent/JP2023113655A/ja active Pending
-
2025
- 2025-04-09 AU AU2025202525A patent/AU2025202525A1/en active Pending
-
2026
- 2026-03-18 JP JP2026045046A patent/JP2026120554A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012972A (es) | 2024-11-08 |
| KR20190141148A (ko) | 2019-12-23 |
| RU2019138312A3 (cg-RX-API-DMAC10.html) | 2022-02-03 |
| KR20250134146A (ko) | 2025-09-09 |
| IL270201B1 (en) | 2026-01-01 |
| WO2018200818A2 (en) | 2018-11-01 |
| JP2023113655A (ja) | 2023-08-16 |
| AU2018256840A1 (en) | 2019-11-07 |
| JP2026120554A (ja) | 2026-07-22 |
| WO2018200818A3 (en) | 2018-12-06 |
| IL270201B2 (en) | 2026-05-01 |
| MX2024003906A (es) | 2024-04-23 |
| EP3615071A2 (en) | 2020-03-04 |
| TW201842932A (zh) | 2018-12-16 |
| BR112019022268A2 (pt) | 2020-05-19 |
| IL270201A (cg-RX-API-DMAC10.html) | 2019-12-31 |
| MX2019012749A (es) | 2020-02-03 |
| US20200179486A1 (en) | 2020-06-11 |
| RU2019138312A (ru) | 2021-05-28 |
| TWI811216B (zh) | 2023-08-11 |
| WO2018200818A9 (en) | 2019-01-17 |
| TW202342102A (zh) | 2023-11-01 |
| AU2025202525A1 (en) | 2025-05-01 |
| CA3061320A1 (en) | 2018-11-01 |
| CN110612120A (zh) | 2019-12-24 |
| JP2020517671A (ja) | 2020-06-18 |
| MX2024003905A (es) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| CY1113253T1 (el) | Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| AR090972A1 (es) | Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| PE20230996A1 (es) | Metodo para el tratamiento de afecciones asociadas a covid-19 | |
| EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| EA201992658A1 (ru) | Методы лечения рекуррентной глиобластомы (rgbm) | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| CY1123583T1 (el) | Ανοσογονος συνθεση για χρηση στη θεραπεια | |
| CO2021016606A2 (es) | Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple | |
| CO2017007383A2 (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
| PE20200889A1 (es) | METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa) | |
| Estenkova et al. | About the SPA and resort-based treatment of the patients with oncological diseases | |
| EA202090452A1 (ru) | Соединения для лечения болезни фон гиппеля-линдау | |
| Kakar et al. | Hypersensitivity to romidepsin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |